Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.

Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data

LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- #Cardiology--HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer.

HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer

Basel, 18 July 2024 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively, the two leading causes of vision loss in adults with diabetes.1-4 Susvimo is the first and only refillable eye implant that provides continuous delivery of a customised formulation of ranibizumab via the Port Delivery Platform.5 The results build on the primary one-year analyses of the Pagoda and Pavilion studies, with Susvimo demonstrating sustained efficacy over two years and safety consistent with the known safety profile for Susvimo in people with DME and DR.6-9 Detailed results were presented at the American Society of Retina Specialists (ASRS) 2024 Annual Meeting in Stockholm, Sweden.

New data for Roche's Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively, the two leading causes of vision loss in adults with diabetes. Susvimo is the first and only refillable eye implant that provides continuous delivery of a cus.

New Data for Genentech's Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Roche's Genentech subsidiary is developing a pill-based diabetes and weight loss drug called CT-996. The new GLP-1 drug is in phase 1 clinical trials and saw patients losing 7% of their weight in four weeks.

Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today new, four-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo® (faricimab-svoa) was well tolerated in people with diabetic macular edema (DME) who received treatment for up to four years. Exploratory results from the long-term study showed that Vabysmo continued to preserve vision, dry retinal fluid that can impair si.

Genentech's Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study

Basel, 17 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, four-year data from the RHONE-X extension study.1 The study met all primary endpoints, showing that Vabysmo® (faricimab) was well tolerated in people with diabetic macular edema (DME) who received treatment for up to four years.2 Exploratory results from the long-term study showed that Vabysmo continued to preserve vision, dry retinal fluid that can impair sight, and allow extended time between treatments in people with DME.2 These data were presented in a late-breaking oral presentation at The American Society of Retina Specialists (ASRS) 2024 Annual Meeting in Stockholm, Sweden.2

Roche's Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study

A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, sending shares of rival GLP-1 developers Eli Lilly and Company (LLY) and Novo Nordisk (NVO) lower Wednesday.

Novo Nordisk, Eli Lilly Slip as Roche Weight-Loss Drug Shows Promise

Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.

Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug

Eli Lilly

Novo Nordisk

The potential of a once-a-day pill for obesity unsettled the weight loss stocks. Shares in Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) were off 4% and 2% respectively on news that Roche's new pill had shown promise in early-stage clinical trials.

Does Roche have weight-loss giants Novo Nordisk and Eli Lilly on the run?

Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its experimental obesity pill.

Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk

Shares of Swiss drugmaker Roche rallied on Wednesday after the company's early-stage trial of an oral weight-loss drug showed it had promise.

Roche shares jump on drugmaker's early-stage data on weight-loss drug

Shares of Swiss pharma giant Roche climbed Wednesday after it reported promising results for an experimental weight loss pill, part of a cohort of hopeful competitors racing to challenge Novo Nordisk and Eli Lilly in the burgeoning diabetes and obesity drug market amid growing evidence the drugs can treat many other health conditions like kidney disease and sleep apnea.

Roche Climbs As Once-Daily Weight Loss Pill Shows Promise

Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss of 6.1% in four weeks.

Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche

Roche said on Wednesday that its CT-996, a GLP-1 receptor agonist to treat obesity and type 2 diabetes, has had positive results in phase one of its clinical trial.

Roche reports positive early results in CT-966 obesity drug trial

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.1 The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinical.

Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity

Basel, 17 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.1 The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks (p

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.

Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark

The collaboration leverages Remix's REMaster™ platform to discover novel drugs for a diverse range of target classes Remix is eligible to receive up to $1 billion in milestone payments and royalties WATERTOWN, Mass. , July 10, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced that it has attained the near-term milestone as part of its collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.

Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration

MALVERN, Pa.--(BUSINESS WIRE)--The Institutes have appointed W. Robert Berkley Jr. as chair, and John C. (Jack) Roche as vice chair, of the organization's Board of Trustees.

W. Robert Berkley and John C. Roche Named Chair and Vice Chair of The Institutes Board of Trustees

Basel, 09 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the CE Mark for its Accu-Chek SmartGuide® continuous glucose monitoring (CGM) solution. This significant milestone paves the way for the solution to be made available to people living with type 1 and type 2 diabetes over the age of 18 on flexible insulin therapy.

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

Genentech, a unit of Roche Group , said on Monday it has reintroduced its ocular implant, Susvimo, in the United States, following the end of a voluntary recall.

Roche reintroduces recalled eye implant in US

Basel, 08 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States (US) with neovascular or ‘wet' age-related macular degeneration (nAMD), following the end of a voluntary recall. The US Food and Drug Administration (FDA) has approved a post-approval supplement to the Biologics License Application for Susvimo, reflecting component-level updates made to the ocular implant and refill needle. Roche will work to make Susvimo available in the US to retina specialists and their patients with nAMD in the coming weeks.

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States (U.S.) with wet, or neovascular, age-related macular degeneration (AMD), following the end of a voluntary recall. The U.S. Food and Drug Administration (FDA) has approved a post-approval supplement to the Biologics.

Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)

The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.

News for Roche Holding AG Stock (RHHBY)